Chlamydial infections and the quinolones.
Some of the newer fluoroquinolones may be suitable agents for the treatment of Chlamydia trachomatis infections and non-gonococcal urethritis. To date, small studies with both ofloxacin and fleroxacin appear to achieve cure rates of 85-100% for urethritis and cervicitis due to Chlamydia trachomatis. However, large well-designed clinical trials are required to determine the efficacy and acceptance of these and other fluoroquinolones in the treatment of patients with genital or respiratory syndromes due to chlamydiae or other bacterial pathogens causing infections with similar manifestations.